Stenting for Ischemic Strokes Secondary to Medically Refractory Intracranial Atherosclerotic Disease (NCT06790147) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Stenting for Ischemic Strokes Secondary to Medically Refractory Intracranial Atherosclerotic Disease
United States150 participantsStarted 2025-08
Plain-language summary
The goal of this observational study is to establish a prospective multicenter registry of patients undergoing intracranial stenting for ischemic strokes caused by medically refractory ICAD. The study aims to evaluate current practice patterns, periprocedural outcomes, and delayed outcomes.
Researchers will collect demographic and procedural data from patients who undergo intracranial stenting after having an ischemic stroke caused by medically refractory ICAD.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adult patients with ICAD resulting in 70-99% vessel stenosis who undergo PTAS with any device
* Patients will have to experience a stroke despite medical management involving risk factor modification and an antiplatelet agent
* Baseline modified Rankin Scale (mRS) ≤ 3
* Performance of the endovascular procedure at least 3 days after the last stroke
Exclusion Criteria:
* Large vessel occlusion strokes undergoing rescue intracranial stenting will not be included
* Baseline modified Rankin Scale (mRS) \>3
* Performance of the endovascular procedure less than 3 days after the last stroke.
* Patients undergoing intracranial stenting for first stroke caused by ICAD
* Adult patients with ICAD resulting in \<70% vessel stenosis
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Recurrent ischemic stroke within treated territory, ICH, or death
Timeframe: 72 hours post procedure
2
Stroke, ICH, or neurological death in treated territory